ASCO 2025

De-escalating therapy - a step forward

Intraoperative dose escalation helps to reach targeted…

WSG: HER2+ pooled analysis

HRD and BRCA status as a new innovative staging system?

TRADE: Abemaciclib in eBC

A new standard for the firstline treatment of HER2+…

Next-gen endocrine therapies and ADCs: Updates from…

A new standard for endocrine-resistant HR+ MBC?

SG + Pembro in aTNBC: a new standard of care?

Triple therapy 1st line | double therapy 2nd line - new…

New compounds - new approaches: TNBC | HR+ | HER2+

AI and ADCs: Precision diagnostics & safer rechallenge…

Additional ADC effective for untreated TNBC

ASCENT-04

New SOC in first-line treatment for primary endocrine…

Final OS-Analysis of INAVO-120 trial

A new first-line therapy for TNBC

Re-exposition and ILD

Liquid biopsy as a navigator for personalized therapy…

New firstline SOC for HER2+ metastatic BC

Vepdegestrant for treatment of ER+/HER2- aBC

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

T-DXd: Detecting ILD and treat again

Effective ADC for HER2+ mBC with brain metastases

SG + Pembrolizumab might become SOC for PD-L1-positive…

Additional chemo-free option for TNBC

Sac-TMT for metastatic TNBC

Future new SOC for PD-L1-positive mTNBC

New AKT/PIK3 Antagonist for treatment of mBC after…

ABC for metastatic TNBC

Ipatasertib + Fulvestrant mejora la supervivencia libre…

Un nouveau traitement de première ligne pour le TNBC

Analisi finale della OS dello studio INAVO-120

Una nuova terapia di prima linea per il TNBC

SG + Pembrolizumab podría convertirse en el tratamiento…

Nuova opzione di trattamento in prima linea per il TNBC…

Vepdegestrant per il trattamento di ER+/HER2- aBC

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

PARP-inhibitor combinations in advanced prostate cancer

Real world data from ironman registry confirms…

Personalized In Situ Immunotherapy SYNC-T Shows High…

News of ANZUP trial

Immuntherapy - an evolution?

MMAI Model identifies patients who benfit from ARPI in…

Adding EZH2 to Enzalutamide to decrease the development…

mHSPC - prognostification - indications on integration?

New way of treatment for PCa

Rebirth of Rucaparib

mHSPC - ADT + NHT updates

Stereotactic beam radiation therapy 2.0

Localized CSPC - innovations

Niraparib + Abiraterone Improves Outcomes in…

Combination of LU-PSMA and immunotherapy, EVOLUTION…

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

ICI Combos in 1L and Maintenance – Mixed Bags or…

Complete but Not Finished: EV+P cCR Data Extend the SOC…

Sasanlimab + BCG: Practice-Changing Potential for…

NIAGARA study and circulating tumor DNA

New option for high-risk NMIBC

ASCO 2025 - Highlights for Bladder Cancer

CREST Study: Promising Results with PD-1 Inhibitor…

New nectin-4 ADCs are coming

UTUC - enlighted

mUC - new approaches?

A new prognostic factor in bladder cancer?: The case of…

Update on EV-PEM in the EV-302 study

Intensive caution of BCG Therapy

mUC EVP + subsequent therapies

Response matters in advanced urothelial cancer patients…

Benefit of IO/IO therapy in mUC

La respuesta es importante en pacientes con cáncer…

El rol de sansalimab (+ SG) en el carcinoma urotelial…

De nouveaux ADC pour la nectine-4 arrivent

ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου…

HIF alfa sigue siendo una diana interesante en el RCC y…

Casdatifan + Cabo – Too Early to Call It a Game…

Who Really Benefits? Pembro’s Solid, Atezo’s Still…

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

Long-term outcome of Nnivo-Ipi in clear cell RCC

Nivo + Ipi - Update & Insights

First lession

Allogeneic CD70 CAR T Cells in refractory RCC

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…

HIF alpha still an interesting target in RCC and other…

Neoadjuvant Approaches in resectable NSCLC: Insights…

cTDNA in periop chemo-IO strategies

Updates in perioperative strategies in NSCLC

CheckMate 816: Update on OS-benefit

CM-816: The OS results are positive and demonstrate…

Neoadjuvant Alectinib in resectable stage III NSCLC

Neadjuvant targeted therapy

ctDNA stratification

Chemoimmunotherapy followed by chemoradiotherapy

CheckMate 816 : Mise à jour sur les avantages du…

Actualizaciones en estrategias perioperatorias en NSCLC

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

RELA-104-biomarker-analysis

TROP2 targets – where is first-line development…

Does the timing of IO-infusion impact survival?

Sevarbertinib – an additional option for HER2 exon 20…

HER3-DXd: dissapointing negative trial

Is there still a place for HER3-DXd in advanced NSCLC?

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

ADC in the 3L beats docetaxel

KRAS G12C: Can immunotherapy improve patient outcome…

Immunotherapy – before or after 3 p.m.?

HERTHENA-Lung02 unfortunately negative study -…

Time of day of immunotherapy is important

Have we MET our target?

Updates on ADCs in EGFR resistance

Benefit of IO is depending on the time of day of…

Actualizaciones sobre los ADC en la resistencia al EGFR

Hebben we ons doel gehaald?

HERTHENA-Lung02 étude malheureusement négative -…

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

New maintenance therapy for SCLC

Taralatamb - the new SOC in 2L treatment

The first positive maintenance therapy in SCLC

Tarlatamab - a new SOC in second line

New therapies to improve patient survival

DeLLphi-304 : Changement radical dans le traitement de…

LA HNSCC - New neoadjuvant SOC